31 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
27214509	1	Synthesis, characterization and antitubercular activities of novel pyrrolyl hydrazones and their Cu-complexes.	S.E.T'S College of Pharmacy
25461892	25	Piperazine derivatives: synthesis, inhibition of the Mycobacterium tuberculosis enoyl-acyl carrier protein reductase and SAR studies.	Pontif£Cia Universidade Cat£Lica Do Rio Grande Do Sul
25282650	8	Development of benzo[d]oxazol-2(3H)-ones derivatives as novel inhibitors of Mycobacterium tuberculosis InhA.	Birla Institute of Technology
24967731	2	Diarylthiazole: an antimycobacterial scaffold potentially targeting PrrB-PrrA two-component system.	Astrazeneca
25221657	3	2-Phenylindole and Arylsulphonamide: Novel Scaffolds Bactericidal against Mycobacterium tuberculosis.	Astrazeneca
25218910	16	Development of 2-(4-oxoquinazolin-3(4H)-yl)acetamide derivatives as novel enoyl-acyl carrier protein reductase (InhA) inhibitors for the treatment of tuberculosis.	Birla Institute of Technology
24450589	64	Encoded library technology as a source of hits for the discovery and lead optimization of a potent and selective class of bactericidal direct inhibitors of Mycobacterium tuberculosis InhA.	Glaxosmithkline
24107081	17	Methyl-thiazoles: a novel mode of inhibition with the potential to develop novel inhibitors targeting InhA in Mycobacterium tuberculosis.	Astrazeneca India
23314046	3	Identification of novel antimycobacterial chemical agents through the in silico multi-conformational structure-based drug screening of a large-scale chemical library.	Kyushu Institute of Technology
22483635	1	Chemical synthesis and biological evaluation of triazole derivatives as inhibitors of InhA and antituberculosis agents.	Cnrs
18457948	27	Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors.	Stony Brook University
20855214	6	2-Hexadecynoic acid inhibits plasmodial FAS-II enzymes and arrests erythrocytic and liver stage Plasmodium infections.	University of London
19428156	30	Discovery of potential new InhA direct inhibitors based on pharmacophore and 3D-QSAR analysis followed by in silico screening.	China Pharmaceutical University
18393405	1	Natural products, small molecules, and genetics in tuberculosis drug development.	National Institute of Diabetes and Digestive and Kidney Diseases
12141869	2	Agonodepsides a and B: two new depsides from a filamentous fungus F7524.	Institute of Molecular and Cell Biology
17560106	1	Synthesis of 4-phenoxybenzamide adenine dinucleotide as NAD analogue with inhibitory activity against enoyl-ACP reductase (InhA) of Mycobacterium tuberculosis.	University of Minnesota
30846404	34	Discovery and development of novel rhodanine derivatives targeting enoyl-acyl carrier protein reductase.	Nanjing University
32240584	7	Fragment-Based Design of	University of Cambridge
31227345	1	Discovery of novel N-methyl carbazole tethered rhodanine derivatives as direct inhibitors of Mycobacterium tuberculosis InhA.	University of Kwazulu-Natal (Ukzn)
31904960	8	Synthesis and Structure-Activity Relationship Studies of C2-Modified Analogs of the Antimycobacterial Natural Product Pyridomycin.	Eth Zurich
24900646	2	Synthesis and antimycobacterial activity of 2,1'-dihydropyridomycins.	Swiss Federal Institute of Technology (Eth) Zurich
29407960	67	An overview on crystal structures of InhA protein: Apo-form, in complex with its natural ligands and inhibitors.	Cnrs
28818767	2	Recent advances of pyrazole-containing derivatives as anti-tubercular agents.	Wuhan University of Science and Technology
29748048	3	Discovery of novel anti-tuberculosis agents with pyrrolo[1,2-a]quinoxaline-based scaffold.	West China Hospital
2188581	23	Muscarinic receptor subtypes.	National Institute For Medical Research